Re: Quality-Adjusted Survival with First-Line Cabozantinib or Sunitinib for Advanced Renal Cell Carcinoma in the CABOSUN Randomized Clinical Trial (Alliance)

被引：0
|
作者：
Laguna, Pilar M.
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 205卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1819 / 1820
页数：3
相关论文
共 50 条
  • [41] Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).
    Chen, Ronald C.
    Feuilly, Marion
    Meng, Jie
    Lister, Johanna
    Marteau, Florence
    Morris, Michael J.
    George, Daniel J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
    Choueiri, Toni K.
    Hessel, Colin
    Halabi, Susan
    Sanford, Ben
    Michaelson, M. Dror
    Hahn, Olwen
    Walsh, Meghara
    Olencki, Thomas
    Picus, Joel
    Small, Eric J.
    Dakhil, Shaker
    Feldman, Darren R.
    Mangeshkar, Milan
    Scheffold, Christian
    George, Daniel
    Morris, Michael J.
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 115 - 125
  • [43] Hypothyroidism and Macrocytosis as Surrogate Markers for Response and Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib as First-line Therapy
    Pinto, A.
    Moreno, V.
    Aguayo, C.
    Garrido, M.
    Espinosa, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S521 - S521
  • [44] First-line therapy in advanced renal cell carcinoma
    Rexer, H.
    Steiner, Th.
    Grunwald, V.
    UROLOGE, 2017, 56 (04): : 509 - 511
  • [45] Cabozantinib: a new first-line option for papillary renal cell carcinoma? Comment
    Borchiellini, Delphine
    Barthelemy, Philippe
    LANCET, 2021, 397 (10275): : 645 - 647
  • [46] Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials
    Manneh Kopp, R.
    Lema Medina, M.
    Ibata, L.
    Martinez, S.
    De Velasco, G.
    Castellano Gauna, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S699 - S699
  • [47] EARLY-ONSET HYPOTHYROIDISM AND SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH FIRST-LINE SUNITINIB: UPDATED OVERALL SURVIVAL DATA
    Pinto, A.
    Garrido, M.
    Cruz, P.
    Lopez, D.
    Zambrana, F.
    Aguayo, C.
    Feliu, J.
    Espinosa, E.
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] Treatment sequencing following first-line sunitinib in patients (pts) with advanced renal cell carcinoma (RCC)
    Gore, M. E.
    Hutson, T. E.
    Lin, X.
    Korytowsky, B.
    Lechuga, M. J.
    Matczak, E.
    Figlin, R. A.
    Bukowski, R.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S660 - S660
  • [49] Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
    Bianconi, Maristella
    Faloppi, Luca
    Loretelli, Cristian
    Zizzi, Antonio
    Giampieri, Riccardo
    Bittoni, Alessandro
    Andrikou, Kalliopi
    Del Prete, Michela
    Burattini, Luciano
    Montironi, Rodolfo
    Scartozzi, Mario
    Cascinu, Stefano
    ONCOTARGET, 2016, 7 (25) : 37599 - 37607
  • [50] CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial
    Choueiri, T. K.
    Halabi, S.
    Sanford, B.
    Hahn, O.
    Michaelson, M. D.
    Walsh, M.
    Olencki, T.
    Picus, J.
    Small, E. J.
    Dakhil, S.
    George, D.
    Morris, M. J.
    ANNALS OF ONCOLOGY, 2016, 27
12345